<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016742</url>
  </required_header>
  <id_info>
    <org_study_id>RDC5-1-01</org_study_id>
    <secondary_id>2013-003335-29</secondary_id>
    <nct_id>NCT02016742</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of the Pharmacokinetics of RDC5 in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Open-label, Randomised, 3-way Crossover Study to Characterise and Compare the Pharmacokinetics, Safety and Tolerability of RDC5 Given as a Single Dose to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chronos Therapeutics Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chronos Therapeutics Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterise the pharmacokinetics, safety and tolerability of
      RDC5 given as a single dose to healthy volunteers at a number of different dose levels
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomised, single dose, 3-way crossover study to characterise and
      compare the PK, safety and tolerability of RDC5 in 15 healthy male volunteers. Eligible
      subjects will undergo 3 Treatment Periods, each separated by a washout period at least 14
      days. Subjects will receive a single dose of RDC5 during each of the three Treatment Periods
      in line with their randomized treatment sequence. A total of 4 dose levels will be evaluated
      within the study, though each subject will only receive 3 doses. A Data Review Team (DRT)
      will review the pharmacokinetic (PK) data from Treatment Periods 1 and 2 and select the doses
      to be evaluated in Treatment Periods 2 and 3. Subjects will return for a follow visit 21 days
      after the last dose of RDC5.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time 0 to infinity (AUC0-inf) for the whole blood concentration of RDC5</measure>
    <time_frame>Up to 6 days post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC from time 0 to time of last observed concentration (AUC0-t)</measure>
    <time_frame>Up to 6 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Up to 6 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which Cmax occurred (tmax)</measure>
    <time_frame>Up to 6 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t1/2)</measure>
    <time_frame>Up to 6 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal phase elimination rate constant (λz)</measure>
    <time_frame>Up to 6 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vd/F)</measure>
    <time_frame>Up to 6 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent oral clearance (CL/F)</measure>
    <time_frame>Up to 6 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number (%) healthy volunteers with treatment emergent adverse events (AEs)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>RDC5 dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of RDC5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDC5 dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of RDC5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDC5 dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of RDC5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDC5 dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of RDC5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDC5</intervention_name>
    <arm_group_label>RDC5 dose level 1</arm_group_label>
    <arm_group_label>RDC5 dose level 2</arm_group_label>
    <arm_group_label>RDC5 dose level 3</arm_group_label>
    <arm_group_label>RDC5 dose level 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to use effective method of contraception

          -  Non smoker or ex-smoker within the previous 6 months

        Exclusion Criteria:

          -  History or presence of any clinically significant findings upon screening

          -  Participation in a New Chemical Entity clinical study within the previous 124 days or
             a marketed drug clinical study within the previous 93 days

          -  Positive result for human immunodeficiency virus (HIV) and/or hepatitis B or C test

          -  Positive result for urine alcohol and drug screen

          -  Blood donation ≥ 450 mL in the previous 12 weeks

          -  Receipt of prescription medicines and/or St John's Wort in the previous 2 weeks
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Girish Sharma</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simbec Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simbec Research Ltd</name>
      <address>
        <city>Merthyr Tydfil</city>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <last_update_submitted>March 11, 2014</last_update_submitted>
  <last_update_submitted_qc>March 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

